Caspofungin

Drugs of Today

Volumn 38, Issue 12, 2002, Pages 829-846

  Chandrasekar, P H ^a   Manavathu, E K ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; L 693986; LY 693986; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; NIKKOMYCIN Z; PAPULACANDIN B; PHENYTOIN; PNEUMOCANDIN DERIVATIVE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; RIFAMPICIN; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE;

ALLERGIC REACTION; ANAPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEVER; FLUSHING; HUMAN; LEUKOPENIA; MYCOSIS; NONHUMAN; PHLEBITIS; PRURITUS; RASH; REVIEW; THROMBOCYTOPENIA;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FUNGI; HUMANS; KIDNEY FAILURE; LIVER FAILURE; MYCOSES; PEPTIDES; PEPTIDES, CYCLIC;

EID: 0037001309     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2002.38.12.820101     Document Type: Review

References (92)

1. Edmond, M.B., Wallace, S.E., McClish, D.K. et al. Nosocomial blood stream infection in United States hospitals. A three-year analysis. Clin Infect Dis 1999, 29: 239-44.
2. McNeil, M.M., Nash, S.L., Hajjeh, R.A. et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001, 33: 641-7.
3. Perfect, J., Schell, W. The new fungal opportunists are coming. Clin Infect Dis 1996, 22(suppl 2): 112-8.
4. Groll, A.H., Walsh, T.J. Caspofungin: Pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001, 10: 1545-58.
5. Stone, E.A., Fung, H.B., Kirschenbaum, H.L. Caspofungin: An echinocandin antifungal agent. Clin Ther 2002, 24: 351-77; discussion 329.
6. Geogopapadakou, N.H. Update on antifungals targeted to the cell wall: Focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs, 2001 10: 269-80.
7. Hoang, A.T. Caspofungin acetate: An antifungal agent. Am J Health-Syst Pharm 2001, 58: 1206-13.
8. Keating, G.M., Jarvis, B. Caspofungin. Drugs 2001, 61: 1121-9.
9. New antimicrobial agents approved by the U. S. Food and Drug Administration in 2001 and new indications for previously approved agents. Antimicrob Agents Chemother 2002, 46: 1160.
10. Bouffard, F.A., Zambias, R.A., Dropinski, J.F., Balkovec, J.M., Hammond, M.L., Abruzzo, G.K., Bartizal, K.F., Marrinan, J.A., Kurtz, M.B., McFadden, D.C., Nollstadt, K.H., Powles, M.A., Schmatz, D.M. Synthesis and antifungal activity of novel cationic pneumocandin BO derivatives. J Med Chem 1994, 37:222-5.
11. Bartizal, K., Abruzzo, G., Trainor, C., Krupa, D., Nollstadt, K., Schmatz, D., Schwartz, R., Hammond, M., Balkovec, J., Vanmiddlesworth, F. In vitro antifungal activities and in vivo efficacies of 1,3-β-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother 1992, 36:1648-57.
12. Bartizal, K., Gill, C.J., Abruzzo, G.K., Flattery, A.M., Kong, L., Scott, P.M., Smith, J.G., Leighton, C.E., Bouffard, A., Dropinski, J.F., Balkovec, J. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997, 41: 2326-32.
13. Del Poeta, M., Schell, W.A., Perfect, J.R. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997, 41: 1835-6.
14. Journet, M., Cai, D., DiMichele, L.M., Hughes, D.L., Larsen, R.D., Verhoeven, T.R., Reider, P.J. Semisynthesis of an antifungal lipopeptide echonocandin. J Org Chem 1999, 64: 2411.
15. Bufford, F.A., Dropinski, J.F., Balkovec, J.M., Black, R.M., Hammond, M.L., Nollstadt, K.H., Dreikorn, S. L-743,872, a novel antifungal lipopeptide: Synthesis and structure-activity relationships of new aza-substituted pneumocandins. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D. C. 1996, Abst. F27: p. 104.
16. Balkovec, J.M., Black, R.M., Hammond, M.L., Heck, J.V., Zambias, R.A., Abruzzo, G., Bartizal, K., Kropp, H., Trainor, C., Schwartz, R.E. Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP). J Med Chem 1992, 35: 194-8.
17. Tawara, S., Ikeda, F., Maki, K., Morishita, Y., Otomo, K., Teratani, N., Goto, T., Tomishima, M., Ohki, H., Yamada, A., Kawabata, K., Takasugi, H., Sakane, K., Tanaka, H., Matsumoto, F., Kuwahara, S. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000, 44: 57-62.
18. De Bono, M., Turner, W.W., LaGranduer, L., Burkhardt, F.J., Nissen, J.S., Nichols, K.K., Rodriguez, M.J., Zweifel, M.J., Zeckner, D.J., Gordee, R.S., Tang, J., Parr, T.R. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): Structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J Med Chem 1995, 38: 3271-81.
19. Bartinicki-Garcia, S. Cell-wall chemistry, morphogenesis, and taxonomy of fungi. Annu Rev Microbiol 1968, 22: 87-108.
20. Borgia, P.T., Dodge, C.L. Characterization of Aspergillus nidulans mutants deficient in cell wall chitin or glucan. J Bacteriol 1992, 174: 377-83.
21. Hector, R.F. Compounds active against cell walls of medically important fungi. J Clin Microbiol Rev 1993, 6: 1-21.
22. Douglas, C.M., Foor, F., Marrinan, J.A., Morin, N., Nielsen, J.B., Dahl, A.M., Baginsky, W., Li, W., elSherbeini, M. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc Natl Acad Sci USA 1994, 91: 12907-11.
23. Inoue, S.B., Takewaki, N., Takasuka, T., Mio, T., Adachi, M., Fujii, Y., Miyato, C., Arisawa, M., Furuichi, Y., Wantanabi, T. Characterization and gene cloning of 1,3-β-D-glucan synthase from Saccharomyces cerevisiae. Eur J Biochem 1995, 231:845-54.
24. Douglas, C.M., D'Ippolito, J.A., Shei, G.J., Meinz, M., Onishi, J., Marrinan, J.A., Li., W., Abruzzo, G.K., Flattery, A., Bartizal, K., Mitchell, A., Kurtz, M. B. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997, 41: 2471-9.
25. Kelly, R., Register, E., Hsu, M.-J., Kurtz, M., Nielsen, J. Isolation of a gene involved in 1,3-β-glucan synthesis in Aspergillus nidulans and purification of the corresponding protein. J Bacteriol 1996, 178: 4381-91.
26. Beauvais, A., Bruneau, J.M., Mol, P.C., Buitrago, M.J., Legrand, R., Latge, J.P. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2001, 183: 2273-9.
27. Enderlin, C.S., Selitrennikoff, C.P. Cloning and characterization of a Neurospora crassa gene required for (1,3) β-glucan synthase activity and cell wall formation. Proc Natl Acad Sci USA 1994, 91: 9500-4.
28. Thompson, J.R., Douglas, C.M., Li, W., Jue, C.K., Pramanik, B., Yuan, X., Rude, T.H., Toffaletti, D.L., Perfect, J.R., Kurtz, M. A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol 1999, 181: 444-53.
29. Mazur, P., Morin, N., Baginsky, W., El-Sherbeini, M., Clemas, J.A., Nelson, J.B., Foor, F. Differential expression and function of two homologous sub-units of yeast 1,3-β-D-glucan synthase. Mol Cell Biol 1995, 15: 5671-81.
30. Tang, J., Parr, T.R., Jr. W-1 solubilization and kinetics of inhibition by cilofungin of Candida albicans (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1991, 35: 99-103.
31. Krishnarao, T.V., Galgiani, J.N. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997, 41: 1957-60.
32. Espinel-Ingroff, A. Comparison of in vitro activities of the new triazole SCH5692 and the echinocandins MK-0991 (L-743,872) and LY30366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998, 36: 2950-6.
33. Pfaller, M.A., Messer, S.A., Gee, S., Joly, S., Pujol, C., Sullivan, D.J., Coleman, D.C., Soll, D.R. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 1999, 37: 870-2.
34. Uzun, O., Kocagoz, S., Cetinkaya, Y., Arikan, S., Unal, S. In vitro activity of a new echinnocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother 1997, 41: 1156-7.
35. Marco, F., Pfaller, M.A., Messer, S.A., Jones, R.N. Activity of MK-0991 (L-743, 872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. - Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Diagn Microbiol Infect Dis 1998, 32: 33-7.
36. Belanger, P., Nast, C.C., Fratti, R., Sanati, H., Ghannoum, M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997, 41: 1840-2.
37. Pfaller, M.A., Marco, F., Messer, S.A., Jones, R.N. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamenentous fungi. Diagn Microb Infect Dis 1998, 30: 251-5.
38. 1, fluconazole, and the pneumocandin MK-O991/caspofungin acetate (L-743 873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother 2000, 44: 739-46.
39. Vazquez, J.A., Lynch, M., Boikov, D., Sobel, J.D. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997, 41: 1612-4.
40. Bartizal, K., Scott, T., Abruzzo, G.K., Gill, C.J., Pacholok, C., Lynch, L., Kropp, H. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother 1995, 39: 1070-6.
41. Ernst, E.J., Klepser, M.E., Ernst, M.E., Messer, S.A., Pfaller, M.A. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999, 33: 75-80.
42. Ernst, E.J., Klepser, M.E., Pfaller, M.A. Post-antifungal effects of echinocandin, azole and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000, 44: 1108-11.
43. Manavathu, E.K., Cutright, J.L., Chandrasekar, P.H. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998, 42: 3018-21.
44. Kurtz, M.B., Heath, I.B., Marrinan, J., Dreikorn, S., Onishi, J., Douglas, C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994, 38: 1480-9.
45. Arikan, S., Lozano-Chiu, M., Paetznick, V., Rex, J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46: 245-7.
46. Franzot, S.P., Casadevall, A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997, 41: 331-6.
47. Stevens, D.A. Drug interaction studies of a glucan synthase inhibitor (LY303366) and a chitin synthase inhibitor (nikkomycin Z) for the inhibition and killing of fungal pathogens. Antimicrob Agents Chemother 2000, 44: 2547-8.
48. Manavathu, E.K., Ganesan, L.T., Cutright, J.L., Chandrasekar, P.H. In vitro antifungal activity of voriconazole in two-drug combination with micafungin, caspofungin and amphotericin B. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 2001: Abst. J-125.
49. Chandrasekar, P.H., Cutright, J.L., Alangaden, G.J., Manavathu, E.K. In vitro susceptibility of clinical isolates of Aspergillus fumigatus to conventional and lipid formulations of amphotericin B in 2-drug combination with caspofungin and micafungin. In: Abstracts of the 12th International Symposium on Infections in the Immunocompromised Host. Int J Infect Dis 2002, 6: 2S45.
50. Manavathu, E.K., Alangaden, G.J., Chandrasekar, P.H. Differential activity of triazoles in 2-drug combination with the echinocandin caspofungin against Aspergillus fumigatus. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 2002: Abst. M-854.
51. Ganesan, L.T., Manavathu, E.K., Cutright, J.L., Chandrasekar, P.H. In vitro synergy of a combination of nikkomycin plus echinocandin against Aspergillus fumigatus. In Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America. Infectious Diseases Society of America, Washington, D.C. 2001: Abst. 649.
52. Chiou, C.C., Mavrogiorgos, N., Tillem, E., Hector, R., Walsh, T.J. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463. Antimicrob Agents Chemother 2001, 45: 3310-21.
53. Chiou, C.C., Groll, A.H., Walsh, T.J. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000, 5:120-35.
54. Ramesh, M.S., Baskaran, I., Ganesan, L., Manavathu, E.K., Chandrasekar, P.H. Postantifungal effect of older and newer antifungal agents on Aspergillus fumigatus and Candida albicans. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 2001, Abst. J-105.
55. Castro, C., Ribas, J.C., Valdivieso, M.H., Varona, R., del Ray, F., Duran, A. Papulacandin B resistance in budding and fission yeasts: Isolation and characterization of a gene involved in (1,3) β-D-glucan synthesis in Saccharomyces cerevisiae. J Bacteriol 1995, 177: 5732-9.
56. Stone, J.A., Holland, S.D., Wickersham, P.J. Sterrett, A., Schwartz, M., Bonfiglio, C., Hesney, M., Winchell, G.A., Deutsch, P.J., Greenberg, H., Hunt, T.L., Waldman, S.A. Single- and multipledose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002, 46: 739-45.
57. Hajdu, R., Thompson, R., Sundelof, J.G., Pelak, B.A., Bouffard, F.A., Dropinski, J.F., Kropp, H. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother 1997, 41: 2339-44.
58. Groll, A.H. Gullick, B.M., Petraitiene, R., Petraitis, V., Candelario, M., Piscitelli, S.C., Walsh, T.J. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob Agents Chemother 2001, 45: 596-600.
59. Package circular: Cancidas® (Caspofungin acetate for infection), January 2001.
60. Balani, S.K., Xu, X., Arison, B.H., Silva, M.V., Gries, A., DeLuna, F.A., Cui, D., Kari, P.H. Ly, T., Hop, C.E., Singh, R., Wallace, M.A. Dean, D.C., Lin, J.H., Pearson, P.G., Baillie, T.A. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000, 28: 1274-8.
61. Stone, J.A., Sallow, C.H., Holland, S.D. et al. Single dose caspofungin pharmacokinetics in healthy elderly subjects. In: Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, September 17-20, 2000: Abst. 853.
62. Stone, J.A., McCrea, J.B., Wickersham, P.J. et al. A phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen. In: Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, September 17-20, 2000: Abst. 854.
63. Stone, J.A., Holland, S., Li, S. et al. Effects of hepatic insufficiency on the pharmacokinetics of caspofungin. In: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, December 16-19, 2001: Abst. 14.
64. Abruzzo, G.K., Flattery, A.M., Gill, C.J., Kong, L., Smith, J.G, Krupa, D., Pikounis, V.B., Kropp, H., Bartizal, K. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589 and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1995, 39: 1077-81.
65. Graybill, J.R., Najvar, L.K., Luther, M.F., Fothergill, A.W. Treatment of murine disseminated candidiasis with L-743,872. Antimicrob Agents Chemother 1977, 41: 1775-7.
66. Abruzzo, G.K., Flattery, A.M., Gill, C.J., Kong, L., Smith, J.G., Pikounis, V.B., Balkovec, J.M., Bouffard, A.F., Dropinski, J.F., Rosen, H., Kropp, H., Bartizal, K. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997, 41: 2333-8.
67. Abruzzo, G.K., Gill, C.J., Flattery, A.M., Kong L., Leighton, C., Smith, J.G., Pikounis, V.B., Bartizal, K., Rosen, H. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000, 44: 2310-8.
68. Graybill, J.R, Bocanegra, R., Luther, M., Fothergill, A., Rinaldi, M.J. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother 1997, 41: 1937-9.
69. Bowman, J.C. Abruzzo, G.K., Anderson J.W., Flattery, A.M., Gill, C.J., Pikounis, V.B., Schmatz, D.M., Liberator, P.A., Douglas, C.M. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: Demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001, 45: 3474-81.
70. Petraitiene, R., Petraitis, V., Groll, A.H., Sein, T., Schaufele, R.L., Francesconi, A., Bacher, J., Avila, N.A., Walsh, T.J. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002, 46: 12-23.
71. Kirkpatrick, W.R., Perea, S., Coco, B.J., Patterson, T.F. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46: 2564-8.
72. Graybill, J.R., Najvar, L.K., Montalbo, E.M., Barchiesi, F.J., Luther, M.F., Rinaldi, M.G. Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob Agents Chemother 1998, 42: 151-3.
73. Kohler, S., Wheat, L.J., Connolly, P., Schnizlein-Bick, C., Durkin, M., Smedema, M., Goldberg, J., Brizendine, E. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother 2000, 44: 1850-4.
74. Gonzalez, G., Tijerina, R., Najvar, L., Bocanegra, R., Rinaldi, M., Graybill, J.R. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment in a mouse model. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000:1671.
75. Powles, M.A., Liberator, P., Anderson, J., Karkhanis, Y., Dropinski, J.F., Bouffard, F.A., Balkovec, J.M., Fujioka, H., Aikawa, M., McFadden, D., Schmatz, D. Efficacy of MI-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998, 42:1985-9.
76. Powles, M.A., McFadden, D.C., Liberator, P.A. et al. L-693,989 for Pneumocystic carinii prophylaxis in rats. Antimicrob Agents Chemother 1994, 38: 1397-404.
77. Villanueva, A., Arathoon, E.G., Gotuzzo, E., Berman, R.S., DiNubile, M.J., Sable, C.A. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001, 33: 1529-35.
78. Arathoon, E.G., Gotuzzo, E., Noriega, L.M., Berman, R.S., DiNubile, M.J., Sable, C.J. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002, 46: 451-7.
79. Villanueva, A., Gotuzzo, E., Arathoon, E. et al. The efficacy, safety and tolerability of caspofungin vs. fluconazole in the treatment of esophageal candidiasis. In: Programs and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, December 16-19, 2001: Abst. 675.
80. Kartsonis, N., Bartizal, K., Hicks, P.S. et al. The efficacy of caspofungin in the treatment of fluconazole-resistant esophageal candidiasis. Annual Meeting of the Infectious Diseases Society of America. San Francisco, California, October 25-28, 2001: Abst. 646.
81. Maertens, J., Raad, I., Sable, C.A. et al. Multicenter, non-comparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory to or intolerant to amphotericin B. amphotericin B lipid formulations or itraconazole. In: Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, September 17-20, 2000: Abst. 1102.
82. Hiemenz J., Raad, I., Boogaerts, M., Maertens, J., Saah, A., Sable, C.A., Chodakewitz, J.A., Severino, M., Saddler, P., Berman, R., DiNubile, M.J., Patterson, T.F., Denning, D., Walsh, T.J. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Focus on Fungal Infections 11. Washington, D.C. 2001: 22.
83. Rubin, M.A., Carroll, K.C., Cahill, B.C. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002, 34: 1160-1.
84. Safdar, A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: Rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis 2002, 34: 1415-7.
85. Goodman, D., Pamer, E., Jakubowski, A., Morris, C., Sepkowitz, K. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002, 35: E35-6.
86. Sable, C.A., Nguyen, B.-Y.T., Chodakewitz, J.A. et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infection. Transpl Infect Dis 2002, 4: 25-30.
87. Drug pricing. Available at http: //www.physician. pdr.net/physician/static/htm?path=controlled/sear chedbook.htm. Accessed June 11, 2002.
88. Fromtling, R.A. Micafungin sodium. Drugs Today 2002, 38: 245-57.
89. Lomaestro, B.M. Caspofungin: An echinocandin antifungal for the treatment of invasive aspergillosis. Formulary, 36: 427-36.
90. Arikan, S., Lozano-Chiu, M., Paetznick, V., Rex, J.H. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001, 45: 327-30.
91. Manavathu, E.K., Cutright, J.L., Loebenberg, D., Chandrasekar, P.H. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000, 46: 229-34.
92. Li, R.K., Rinaldi, M.G. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 1999, 43: 1401-5.